{
    "nct_id": "NCT05020236",
    "official_title": "AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR",
    "inclusion_criteria": "* Prior diagnosis of multiple myeloma as defined by IMWG criteria (Rajkumar et al, 2014).\n* Measurable disease based on IMWG criteria as defined by at least 1 of the following:\n\n  * Serum M-protein ≥0.5 g/dL.\n  * Urinary M-protein excretion ≥200 mg/24 hours.\n  * Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).\n* Prior anti-multiple myeloma therapy including treatment with lenalidomide and a proteasome inhibitor.\n* ECOG performance status ≤2.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.\n* Not pregnant and willing to use contraception.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Smoldering multiple myeloma.\n* Plasma cell leukemia.\n* Amyloidosis.\n* POEMS Syndrome.\n* Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.\n* Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection.\n* Any other active malignancy within 3 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.\n* Previous treatment with a BCMA-directed therapy.\n* Anti-CD38-directed therapy within 6 months preceding the first dose of treatment in this study.\n* Live attenuated vaccine within 4 weeks of the first dose of study intervention.\n* Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.",
    "miscellaneous_criteria": ""
}